Carcinoma in Situ
As J&J aims to ‘fundamentally change’ how bladder cancer type is treated, ImmunityBio plays defense
TAR-200, bladder cancer, gemcitabine releasing system, non-muscle invasive bladder cancer (NMIBC), Johnson & Johnson, ImmunityBio, Anktiva, BCG-unresponsive, carcinoma in situ (CIS), bladder-sparing treatment